Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Portfolio Pulse from
A class action lawsuit has been filed against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 10, 2025 | 11:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia's stock may face continued pressure due to the class action lawsuit alleging securities fraud and the company's strategic shift away from NTLA-3001 research.
The lawsuit and strategic changes suggest potential ongoing financial and reputational challenges for Intellia Therapeutics, which could negatively impact investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100